Allogeneic marrow transplantation for acute nonlymphoblastic leukemia.

@article{Fefer1986AllogeneicMT,
  title={Allogeneic marrow transplantation for acute nonlymphoblastic leukemia.},
  author={Alexander Fefer},
  journal={Journal of the National Cancer Institute},
  year={1986},
  volume={76 6},
  pages={1275-9}
}
Bone marrow transplantation (BMT) from an HLA-matched sibling donor can cure 15% of end-stage patients with refractory acute leukemia. Failures are largely due to acute or chronic graft-versus-host disease, idiopathic or cytomegalovirus-associated interstitial pneumonitis, veno-occlusive disease of the liver, opportunistic infections, and leukemia relapse. The post-BMT leukemia relapse rate has been reduced from 65% to 20-40% by performing BMT in first complete remission (CR). Overall, about 50… CONTINUE READING